News | Breast Imaging | April 02, 2021

Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48% of interval cancers and 93% of subgroups that include false-negatives and minimal sign lesions

 iCAD, Inc. announced that ProFound AI for 2D Mammography might notably reduce the risk of interval breast cancer, according to a retrospective analysis recently published in the Journal of Medical Screening. 

April 2, 2021 — iCAD, Inc. announced that ProFound AI for 2D Mammography might notably reduce the risk of interval breast cancer, according to a retrospective analysis recently published in the Journal of Medical Screening

The aim of the study was to determine if adding artificial intelligence (AI) to reading mammography as a supportive tool may help in decreasing the interval cancer rate in population-based organized mammography screening programs in Germany.

“Interval breast cancers—cancers that are diagnosed after a negative mammography screening, but before the next recommended screening exam, can be linked to a poor prognosis such as cancer that has already spread, or a more aggressive type of cancer, thus underscoring the need for iCAD’s deep-learning algorithm that can analyze each mammography image and provide critical insight into individual cases,” said Michael Klein, Chairman and CEO of iCAD. “The data from this retrospective analysis are very encouraging in Europe while also having an impact on screening in the US. The results further stress the importance of our ProFound AI platform as a world-class artificial intelligence (AI) solution offering benefits to radiologists and women in improving breast cancer detection rates, reducing false positives and unnecessary callbacks, and providing more personalized screening for every woman.”  

In the retrospective analysis, which evaluated a screening period from 2011 and 2012, a total of 37,367 women between the ages of 50-69 were screened with full-field digital mammography (FFDM). Of these, 29 cases of interval cancers with full documentation were evaluated using ProFound AI for 2D Mammography. For quality assurance, interval cancers with the prior screening mammogram were classified in four categories by the radiologists: true interval cancers, minimal sign cancers, missed cancers (false negative) based on the original screening exam deemed as normal and dismissed, and occult cancers. The objective of the study was to determine whether ProFound AI for 2D Mammography could identify interval cancers that had either minimal signs in the original normal screening or were missed in the original screening round where they had been dismissed as a normal exam.

According to the lead author of the study, Axel Gräwingholt, M.D., Radiologie am Theater in Paderborn, Germany, “The results indicate that ProFound AI for 2D Mammography found 93% of these cancers—eight out of nine cancers that presented minimal signs and six out of six that were false negatives, or missed in the screening round—demonstrating that some cancers could have been detected earlier within the screening round where they were dismissed as normal and therefore wouldn´t have been detected as interval cancers.”

“As a result, ProFound AI as a clinical tool for radiologists has the potential to reduce interval cancer rates by detecting cancers that are already present in the screening round but are perhaps undetected or missed by the readers,” continued Dr. Gräwingholt. “Using this technology at the screening level could limit the number of false negatives and help to detect a large proportion of the minimal sign cancers, which could ensure earlier treatment and better chances of recovery for these women.”

“This study contributes to the growing body of evidence that demonstrates the clear value ProFound AI for 2D Mammography can offer to screening programs across Europe, benefiting both the patient and the clinician,” said Michele Debain, Vice President of Europe, Middle East and Africa at iCAD. “It is essential to detect breast cancers as early as possible, as the cancer can grow, develop and spread. Earlier cancer detection allows for earlier treatment, which in turn could lead to less stress for the patient and lower costs for the national health systems. In addition, the rate of interval cancers is typically used as a measure for the quality of the national mammography screening program.” 

iCAD’s Breast Health Solutions suite includes ProFound AI for Digital Breast Tomosynthesis (DBT) and software solutions for 2D mammography, risk evaluation and breast density. In 2018, ProFound AI for DBT received its CE mark, Health Canada approval and was the first 3D tomosynthesis software using AI to receive clearance from the U.S. Food and Drug Administration (FDA). ProFound AI for 2D Mammography received a CE mark in July 2019. In a reader study published in Radiology, ProFound AI for DBT was shown to offer clinically proven time-savings benefits to radiologists, reducing reading time by 52.7 percent, improving radiologist sensitivity by 8 percent, and reducing false positives and unnecessary patient recall rates by 7.2 percent.

For more information: www.icadmed.com

Related Content

Sponsored Content | Videos | Magnetic Resonance Imaging (MRI)

With the recent launch of the Magnifico Open, Italian company Esaote has entered the open MRI whole body space. ITN had ...

Time January 24, 2022
arrow
News | Radiology Business

January 21, 2022 — IBM and Francisco Partners, a leading global investment firm that specializes in partnering with ...

Time January 21, 2022
arrow
News | Ultrasound Imaging

January 21, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), preoperative shear wave ...

Time January 21, 2022
arrow
Sponsored Content | Case Study | Computed Tomography (CT)

Approximately thirteen men out of every 100 will get prostate cancer during their lifetime, and about two to three men ...

Time January 21, 2022
arrow
Feature | Breast Imaging | By Bhvita Jani

The rising global incidence rates of breast cancer, coupled with the severe backlog of women requiring breast cancer ...

Time January 20, 2022
arrow
News | Artificial Intelligence

January 20, 2022 — Leading health tech firm Qure.ai has gained 510(k) clearance from the Food and Drug Administration ...

Time January 20, 2022
arrow
Feature | Radiology Business | By Jef Williams

The Great Resignation has impacted every industry, including ours. While this movement will be studied for years to come ...

Time January 20, 2022
arrow
Feature | Artificial Intelligence | By Dave Fornell, ITN Editor

Artificial intelligence (AI) has found a unique niche to help automate the activation of acute care teams for pulmonary ...

Time January 19, 2022
arrow
Feature | Coronavirus (COVID-19) | By Avielle Siegel, Paul J. Chang, David M. Paushter, et al.

A 26-year-old man with history of diabetes and hypertension presented with 7 days of fever, chills, nausea, intractable ...

Time January 19, 2022
arrow
Sponsored Content | Case Study | Ultrasound Imaging

The most common cause of chronic liver disease? Nonalcoholic fatty liver disease (NAFLD). With 25% of the world’s ...

Time January 19, 2022
arrow
Subscribe Now